Substituted cyclohexyl chemical entities of Formula (I): wherein R.sup.a, G, and R.sup.b have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

##STR00001##

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure has a high glass transition temperature that can be used in a deposition process. Further, by comprising the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having a low driving voltage, high luminous efficiency, and/or improved lifespan characteristics can be provided.

A crystal form (such as formula I) of a 2-methyl-2-propanol and amino-substituted aryl compound and a preparation method therefor. Also provided is an application of the crystal form in the preparation of a medicine for treating related diseases.

Substituted cyclohexyl chemical entities of Formula (I):

##STR00001## wherein R.sup.a, G, and R.sup.b have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Provided in the present disclosure is an organic compound, which relates to the technical field of organic materials. In the compound of the present disclosure, an electron-deficient nitrogen-containing heteroaryl and cyano are linked to adamantly, so that the LUMO energy level is deepened, thereby electron mobility is further improved. Further provided in the present disclosure are an electronic component and electronic apparatus comprising the described organic compound. The organic compound can improve the electron transport performance of electronic components. When used as an electron transport layer of an organic light-emitting electroluminescent device, the compound can improve the luminous efficiency and service life of the device and reduce the working voltage.

Disclosed are compounds, for example, compounds of formula I, ##STR00001##
wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed are compounds, for example, compounds of formula I, ##STR00001##
wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, when Q is: (i) halo, cyano, hydroxyl, NR.sup.xR.sup.x, C(O)OH, C(O)NH.sub.2, C.sub.1-6 alkyl substiuted with zero to 6 R.sup.1a, or P(O)R.sup.1cR.sup.1c, or (ii) L R.sup.1; and A, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Z.sup.1, Z.sup.2, R.sup.1, R.sup.1a, R.sup.1c, R.sup.2, R.sup.3a, R.sup.3b, R.sup.x, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

##STR00001##